Research in this project is currently focused on four areas. These are characterization of the survivors of the anthrax attacks of 2001; evaluation of the factors underlying pathogenicity in cytokine expressing ectromelia; characterization of emerging respiratory infections including SARS and influenza; and development of novel therapies for avian flu. The anthrax study has enrolled a cohort of volunteers who are currently undergoing an extensive diagnostic evaluation. A study in non-human primates determined that post-exposure vaccination plus antibiotics was superior to antibiotics alone as a means of preventing the development of inhalational anthrax following exposure to anthrax spores. To be ready to deal with emerging infectious diseases of the respiratory tract, a protocol has been developed to systematically study patients presenting with a compatible symptom complex. This protocol has been complemented by the development of treatment protocol that will utilize hyperimmune Ig to the SARS virus. In response to the threat of avian influenza, in collaboration with the World Health Organization, the Welcome Trust and a series of academic and government organizations, a clinical research network has been established in SE Asia that will be able to conduct studies focused on the characterization and treatment of emerging influenza outbreaks. The first protocol in this network will examine the effects of standard vs. double dose oseltamivir in treating severe cases of influenza. To explore novel therapeutic approaches to avian influenza a protocol is in development to hyperimmunize normal volunteers with an H5N1 vaccine. If a strong immune response can be generated in this way; the plasma from these volunteers will be utilized to generate a hyperimmune Ig.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Intramural Research (Z01)
Project #
1Z01AI000936-04
Application #
7592292
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
2007
Total Cost
$324,999
Indirect Cost
City
State
Country
United States
Zip Code
Vietri, Nicholas J; Purcell, Bret K; Lawler, James V et al. (2006) Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax. Proc Natl Acad Sci U S A 103:7813-6
Beigel, John H; Farrar, Jeremy; Han, Aye Maung et al. (2005) Avian influenza A (H5N1) infection in humans. N Engl J Med 353:1374-85
Bray, Mike (2005) Pathogenesis of viral hemorrhagic fever. Curr Opin Immunol 17:399-403
Bray, Mike (2004) Henry Kempe and the birth of vaccinia immune globulin. Clin Infect Dis 39:767-9
Bray, Mike; Buller, Mark (2004) Looking back at smallpox. Clin Infect Dis 38:882-9
Mahanty, Siddhartha; Bray, Mike (2004) Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis 4:487-98
Edghill-Smith, Yvette; Venzon, David; Karpova, Tatiana et al. (2003) Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques. J Infect Dis 188:1181-91
Bray, Mike; Wright, Mary E (2003) Progressive vaccinia. Clin Infect Dis 36:766-74
Masur, Henry; Emanuel, Ezekiel; Lane, H Clifford (2003) Severe acute respiratory syndrome: providing care in the face of uncertainty. JAMA 289:2861-3